Visceral Fat Percentage Range: UK Health Guide

Visceral fat percentage range is a key measure of metabolic health, yet it is widely misunderstood and difficult to assess accurately outside specialist settings. Unlike subcutaneous fat, visceral fat sits deep within the abdominal cavity, surrounding vital organs, and is strongly linked to type 2 diabetes, cardiovascular disease, and liver conditions. This article explains what constitutes a healthy visceral fat level for UK adults, how it is measured, what drives its accumulation, and when to seek clinical advice.

What is visceral fat and why does it matter for your health?

Visceral fat is metabolically active fat stored around abdominal organs that releases inflammatory chemicals, driving insulin resistance and raising the risk of type 2 diabetes, cardiovascular disease, and liver disease, even in people with a normal body weight.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas, and intestines, and it carries significantly greater health risks than subcutaneous fat stored just beneath the skin. Unlike subcutaneous fat, which you can pinch, visceral fat is not visible from the outside and cannot be felt on examination. It is sometimes called "active" fat because it releases inflammatory chemicals and hormones, including cytokines and free fatty acids, that interfere with normal metabolic function.^[1][4]

The health consequences of excess visceral fat are well established. Elevated levels are independently associated with an increased risk of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (now also termed metabolic dysfunction-associated steatotic liver disease, or MASLD), and certain cancers.^[4][2] NICE guidance on obesity and a substantial body of peer-reviewed evidence highlight that individuals with high visceral fat can face these risks even when their overall body weight appears within a normal range. This pattern is sometimes described as being metabolically at risk despite a normal weight, because standard weight measures do not capture where fat is stored.

Visceral fat is hormonally active and contributes to insulin resistance by releasing excess free fatty acids directly into the portal circulation, which flows straight to the liver.^[3][1] This disrupts glucose regulation and lipid metabolism. Because of this direct metabolic pathway, reducing visceral fat tends to produce improvements in blood glucose, blood pressure, and cholesterol levels, often before significant changes in overall body weight are apparent.

Understanding visceral fat as distinct from total body fat is therefore clinically important, and measuring it accurately requires more than a standard bathroom scale.

What is a healthy visceral fat percentage range for adults in the UK?

No single NHS-endorsed visceral fat percentage range exists; waist circumference above 88 cm in women and 102 cm in men indicates substantially increased metabolic risk, with lower thresholds for South Asian and East Asian populations.

There is no single universally agreed visceral fat percentage range endorsed by NICE or NHS England. This is partly because visceral fat measurement methods differ considerably in accuracy and accessibility, and partly because consumer devices express results as proprietary "ratings" or estimates rather than validated clinical percentages.

Some body composition monitors display a visceral fat "rating" (for example, a scale of 1 to 12 described as healthy and 13 or above as high). These ratings are specific to individual manufacturers and are not standardised across clinical practice or equivalent to a clinically validated percentage. If your device uses such a scale, refer to the manufacturer's own documentation to interpret your result, and treat it as a rough guide rather than a clinical measurement.

The most accurate methods for quantifying visceral fat include magnetic resonance imaging (MRI) and computed tomography (CT) scanning, which are used in research settings but are not routinely available for this purpose in NHS clinical practice. Dual-energy X-ray absorptiometry (DEXA) scanning offers a more accessible alternative and is increasingly used in specialist weight management services. Consumer-grade bioelectrical impedance scales provide an estimate of visceral fat, but their accuracy is limited by hydration status, recent exercise, timing relative to meals, and the proprietary algorithms each manufacturer uses. Results from different devices are not directly comparable.

In everyday clinical practice, waist circumference remains the most practical proxy measure for visceral adiposity. NICE guidance recommends that a waist circumference above 88 cm (35 inches) in women and above 102 cm (40 inches) in men indicates substantially increased metabolic risk.^[6][5] For people of South Asian, Chinese, Japanese, or other East Asian backgrounds, lower thresholds apply: NICE and WHO guidance supports cut-offs of approximately 80 cm in women and 90 cm in men from these groups, reflecting evidence that visceral fat accumulates at lower overall body weights in these populations.^[6][5]

Waist-to-height ratio is also used as a simple screening tool. NHS guidance suggests that a waist-to-height ratio below 0.5 is generally considered healthy for most adults. This measure may be more informative than waist circumference alone because it accounts for differences in height.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where body composition concerns can be discussed as part of a broader clinical assessment.

What raises your visceral fat levels and how can you tell?

Ultra-processed diets, physical inactivity, poor sleep, chronic stress, excess alcohol, and hormonal changes such as the menopause all raise visceral fat; increasing waist circumference and raised fasting glucose or triglycerides are key indicators.

Several modifiable and non-modifiable factors drive visceral fat accumulation, with diet quality, physical inactivity, sleep disruption, chronic stress, alcohol consumption, and hormonal changes among the most significant contributors. A diet high in ultra-processed foods, refined carbohydrates, and added sugars promotes visceral fat deposition by driving insulin resistance and encouraging preferential fat storage around the abdominal organs. Excess alcohol intake, even without obesity, is a well-recognised contributor to increased visceral and liver fat.

Chronic psychological stress raises cortisol levels, and sustained cortisol elevation is associated with visceral fat accumulation.^[4] This is one reason why people under prolonged stress may gain abdominal fat even without significant changes in diet. Poor sleep quality and short sleep duration (typically defined as fewer than six hours per night in research studies) are also associated with higher visceral fat, likely through effects on appetite-regulating hormones such as leptin and ghrelin.

Hormonal changes play a meaningful role. In women, the menopause transition is associated with a redistribution of fat from subcutaneous to visceral depots, even without weight gain. In men, declining testosterone levels with age have a similar effect. Genetic factors also influence where the body preferentially stores fat, which is why some individuals accumulate visceral fat at lower overall body weights.

Measurements that may suggest elevated visceral fat include:

• Increasing waist circumference, particularly above the thresholds described in the section above

• An apple-shaped body distribution, with fat concentrated around the abdomen rather than the hips and thighs

• Raised fasting blood glucose, triglycerides, or blood pressure identified on routine blood tests

Non-specific symptoms such as fatigue or difficulty managing blood sugar levels can have many causes and are not reliable indicators of visceral fat on their own. If you notice any of these measurements or symptoms, a GP assessment is the appropriate next step to determine the underlying cause.

Because visceral fat is internal, physical appearance alone is not a reliable indicator, and some individuals with a normal BMI may still carry clinically significant visceral fat.

How can you reduce visceral fat through diet, exercise, and lifestyle?

Visceral fat responds well to a calorie-controlled Mediterranean-style diet, at least 150 minutes of moderate aerobic activity per week, resistance training, and seven to nine hours of quality sleep per night.

Visceral fat responds well to lifestyle intervention, and evidence suggests it is more readily mobilised than subcutaneous fat, meaning targeted changes in diet, physical activity, and sleep can produce measurable reductions. A calorie-controlled diet that reduces overall energy intake, broadly in line with NICE weight management guidance, supports gradual fat loss including visceral fat reduction. NICE guidance on obesity management (NG246) recommends an energy deficit approach as part of a structured programme, though the specific deficit should be agreed with a clinician based on individual circumstances.^[5][7]

Dietary approaches with the strongest evidence include:

• Reducing intake of ultra-processed foods, refined sugars, and sugar-sweetened beverages

• Following a Mediterranean-style dietary pattern, rich in vegetables, legumes, whole grains, oily fish, and unsaturated fats

• Limiting alcohol to within UK Chief Medical Officers' low-risk guidelines (no more than 14 units per week, spread across at least three days)^[11]

• Prioritising dietary fibre, which supports gut health and reduces postprandial insulin spikes

Physical activity is particularly effective at reducing visceral fat, often independently of weight loss. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training have demonstrated benefits. NHS and NICE guidance recommends at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days.^[10][7] High-intensity interval training (HIIT) has shown promising results for visceral fat reduction in a number of studies, though any sustained increase in physical activity is beneficial regardless of the format.^[19][21]

Sleep and stress management are frequently overlooked but clinically important. Aiming for seven to nine hours of good-quality sleep per night and incorporating evidence-based stress reduction techniques, such as mindfulness-based cognitive therapy or structured relaxation, can support visceral fat reduction alongside dietary and exercise changes. Where lifestyle measures alone are insufficient, a GP or specialist may consider pharmacological support as part of a structured weight management programme.

When should you speak to a GP about your visceral fat levels?

See your GP if your waist circumference exceeds NICE thresholds, blood glucose, blood pressure, or cholesterol is elevated, or sustained lifestyle changes have not improved your measurements.

You should speak to your GP about visceral fat if your waist circumference exceeds the NICE risk thresholds, if you have been told your blood glucose, blood pressure, or cholesterol is elevated, or if you have tried sustained lifestyle changes without meaningful improvement in your measurements. These findings may indicate that visceral fat is contributing to metabolic risk that warrants clinical assessment and, where appropriate, investigation or treatment.

Your GP can arrange relevant blood tests, including fasting glucose, HbA1c, a full lipid profile, and liver function tests, which together help to build a picture of metabolic health. Where MASLD (previously called non-alcoholic fatty liver disease) is suspected, current NICE-aligned practice uses blood-based fibrosis risk scores such as FIB-4 or the Enhanced Liver Fibrosis (ELF) test for initial risk stratification, before considering imaging.^[12] Ultrasound or other imaging may be arranged where clinically indicated, for example to exclude other diagnoses. Where results suggest significant metabolic risk, referral to a specialist weight management service or a dietitian may be appropriate under NHS pathways.

For some individuals, pharmacological treatment may be considered alongside lifestyle intervention. Medicines such as semaglutide (Wegovy, available in doses up to 2.4 mg weekly by subcutaneous injection, with a higher-dose 7.2 mg weekly option also authorised in the UK) and tirzepatide (Mounjaro, authorised in the UK for both type 2 diabetes and chronic weight management) have demonstrated reductions in visceral fat in clinical trials, in addition to their effects on overall body weight.^[16][17] These are prescription-only medicines and are subject to eligibility criteria and clinical assessment. Mounjaro may be one option a prescriber considers after an online consultation with Bolt Pharmacy, and is only prescribed where clinically appropriate.

Contact your GP (rather than using urgent services) if you notice:

• Persistent increase in waist circumference despite lifestyle changes

• New or worsening symptoms such as fatigue, increased thirst, or frequent urination

• Abnormal results from a home blood pressure monitor or blood glucose device

If you experience chest pain, sudden breathlessness, or other symptoms suggesting a cardiac event, call 999 immediately. For urgent but non-emergency health concerns outside GP hours, contact NHS 111. Suspected adverse effects from any medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue.
2. Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance.
3. A causative link between visceral adiposity and hepatic insulin resistance (portal hypothesis).
4. Visceral obesity: a "civilization syndrome".
5. Overweight and obesity management (NG246).
6. NG246 – Identifying and assessing overweight, obesity and central adiposity (chapter).
7. NG246 – Physical activity and diet (chapter).
8. Calculate your waist to height ratio.
9. Keep the size of your waist to less than half of your height – NICE recommends.
10. Physical activity guidelines for adults aged 19 to 64.
11. Alcohol consumption: advice on low risk drinking.
12. Metabolic dysfunction-associated steatotic liver disease (NG49) – recommendations for research.
13. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
14. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
15. Semaglutide – Drugs – BNF.
16. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
17. Tirzepatide – Drugs – BNF.
18. Mounjaro – European Medicines Agency EPAR.
19. Effect of High-Intensity Interval Training on Total, Abdominal and Visceral Fat Mass (Maillard et al.).
20. Comparative Efficacy of Exercise Type on Visceral Adipose Tissue in Patients With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review With Pairwise and Network Meta-Analyses.
21. Effect of low-volume interval training on whole-body, abdominal and visceral fat in adults living with overweight and obesity: A systematic review and meta-analysis.
22. Efficacy of Interval Training in Improving Body Composition and Adiposity in Apparently Healthy Adults: An Umbrella Review with Meta-Analysis.
23. Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff et al.).

Frequently Asked Questions